23 April 2020

Effective 1 April 2020, Martin Boeree has been appointed professor of Clinical Tuberculosis and other Mycobacterial Diseases at Radboud University/Radboudumc. He is the first professor in this field in the Netherlands.

Martin Boeree is searching for shorter and better treatments for drug sensitive and resistant tuberculosis. He is also conducting interdisciplinary research on treatment and clinical relevance in the area of non-tuberculous mycobacteria: bacteria that are related to tuberculosis that cause infections other than tuberculosis. These types of infections are becoming increasingly common in the Netherlands. Martin Boeree heads the Centre of Expertise for Mycobacterial Diseases.

On Martin Boeree
Martin Boeree (1958, Eelde) studied Medicine at the University of Groningen, and followed specialist training in the Lichtenberg Hospital in Amersfoort and the Academic Hospital Groningen, where he was registered as a pulmonologist in 1994. He also completed the study  Tropical Medicine and International Health at the KIT Royal Tropical Institute in Amsterdam, where he was registered as a tropical medicine specialist in 1994. In 2003, he completed his PhD with a study on tuberculosis control in Africa during the peak of the HIV epidemic.

In 1995, Boeree left to spend five years in Malawi. He worked as a specialist in the Internal Medicine department of the medical faculty in Blantyre, and he became head of the department in 1997.
After working in the Twenteborg Hospital in Almelo for a year, he was appointed as a pulmonologist/assistant professor in Radboudumc and the Dekkerswald Academic Pulmonology Center in 2001. He served as the Director of Dekkerswald from 2005 to 2010.
Since 2011, he has worked as an associate professor of Clinical Tuberculosis and Mycobacterial Diseases and he has been a Principal Investigator since 2012.

Martin Boeree is the coordinator of the multi-centre PanACEA consortium, where he seeks to make a substantial contribution to the WHO End TB strategy, which is aimed at eliminating tuberculosis by 2035.
  • Want to know more about these subjects? Click on the buttons below for more news.

    Pulmonary Diseases

Related news items

Radboudumc guides Indonesian PhD candidates in fight against tuberculosis  More than 25 years of scientific research and knowledge sharing  

8 October 2023

Radboudumc has been collaborating with universities from Tanzania, Suriname and Indonesia for 25 years. Collaboration entails exchanging knowledge and healthcare professionals, lecturers, researchers and students; two Indonesian candidates received their PhD degrees in Nijmegen recently.

read more

Computer determines the right dosage of antibiotics for ICU patients PhD thesis defense of Eveline Wallenburg on August 29 at 2:30 p.m.

29 August 2022

One third of patients with an infection in the intensive care unit die. In her thesis 'Revisiting antimicrobial therapy in critically ill patients through pharmacometrics', Eveline Wallenburg shows that intensive care patients often receive the wrong dosage of antibiotics. 

read more

Anti-tuberculosis drug can be safely dosed even higher

16 March 2021 A considerably higher dose of the anti-tuberculosis drug rifampicin is safe and can also lead to a shorter treatment for tuberculosis and less resistance. read more

Tuberculosis medication safe in higher dosage

28 March 2019 For more than 40 years, patients with tuberculosis have been prescribed almost the same dose of rifampicin. Some studies suggest that the dose is too low and not optimal. read more

The potential for shortening tuberculosis treatment with higher rifampicin doses

5 July 2018 In Clinical Infectious Diseases Elin Svensson and colleagues showed that increasing rifampicin exposure shortened the time needed to reach undetectable levels of bacteria in sputum. read more

Tuberculosis research Martin Boeree on Euronews

7 December 2017 One of the Sustainable Development Goals is a world without tuberculosis in 2030. read more